591767-62-3

Basic information

• Product Name: Isoquinoline, 6-methoxy-, 2-oxide (9CI)
• Synonyms: Isoquinoline, 6-methoxy-, 2-oxide (9CI);6-Methoxyisoquinoline 2-oxide
• CAS NO: 591767-62-3
• Molecular Formula: C10H9NO2
• Molecular Weight: 175.18396
• Product Categories: METHOXY
• Mol File: 591767-62-3.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Isoquinoline, 6-methoxy-, 2-oxide (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Isoquinoline, 6-methoxy-, 2-oxide (9CI)(591767-62-3)
• EPA Substance Registry System: Isoquinoline, 6-methoxy-, 2-oxide (9CI)(591767-62-3)

Safety Data

• Hazardous Substances Data: 591767-62-3(Hazardous Substances Data)

Upstream product

• 52986-70-6 6-methoxyisoquinoline 
• 2311-91-3 monoperoxyphthalic acid 
• 42923-77-3 6-methoxy-1,2,3,4-tetrahydro-isoquinoline 
• 123-11-5 4-methoxy-benzaldehyde 
• 54879-77-5 N-(4-methoxybenzyl)aminoacetaldehyde dimethyl acetal 

Relevant articles and documents

Palladium-Catalyzed Enantioselective C(sp3)-H Arylation of 2-Propyl Azaaryls Enabled by an Amino Acid Ligand

A palladium(II)-catalyzed enantioselective arylation of unbiased secondary C(sp3)-H bonds was developed. The enantioselectivity was controlled by the combination of a pyridyl or isoquinolinyl directing group and an amino acid, N-Boc-2-pentyl proline. A variety of 2-propyl azaaryls and biaryl iodides were employed to provide arylated products in moderate to good yields (up to 82%) with high enantioselectivities (up to 93:7 er). This reaction is a rare example of an amino-acid-enabled enantioselective acyclic methylene C(sp3)-H arylation. Furthermore, the reaction proceeded with high enantioselectivity even on a gram scale, and the product was transformed to a 5,6,7,8-tetrahydroisoquinoline bioactive molecule. Kinetic isotope effect (KIE) experiments indicated that C-H activation is the rate-determining step for the enantioselective C(sp3)-H arylation.

SUBSTITUTED ARYLMETHYLUREAS AND HETEROARYLMETHYLUREAS, ANALOGUES THEREOF, AND METHODS USING SAME

The present invention includes substituted arylmethyl ureas and heteroarylmethyl-ureas, and compositions comprising the same, that can be used to treat or prevent hepatitis B virus (HBV) infections in a patient.

New substituted isoquinoline and isoquinolinone derivatives

The invention relates to 6-substituted isoquinoline and isochinolone derivatives of the formula (I) useful for the treatment and/or prevention of diseases associated with Rho-kinase and/or Rho-kinase mediated phosphorylation of myosin light chain phosphatase, and compositions containing such compounds.